Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients
become gradually lymphopenic after a few days of treatment, with selective reductions in
CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells
after fingolimod administration. However, we also found that half of patients had increased
proportion of circulating Th17 cells in CD4+ T cells after treatment (including a patient with
MS relapses), whereas the others showed lower frequencies of Th17 cells, indicating some …